Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc., decided July 8, 2025

This patent infringement case between Janssen Pharmaceuticals and Teva Pharmaceuticals USA, Inc. was consolidated with a similar case against Mylan Laboratories Ltd. The core of the dispute centers on Janssen's U.S. Patent No. 9,439,906, which covers dosing regimens for long-acting injectable antipsychotic medications. The appeal specifically addresses the District Court's finding that Teva failed to prove the patent invalid for obviousness, particularly regarding the unequal, decreasing loading doses and renal impairment dosage adjustments outlined in the patent claims. The appellate court affirms the lower court's decision, concluding that Teva did not provide clear and convincing evidence to establish obviousness. Case summary: https://www.cafcnewsbriefs.com/post/janssen-pharmaceuticals-inc-v-teva-pharmaceuticals-usa-inc-decided-july-8-2025